| pubmed-article:20309652 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20309652 | lifeskim:mentions | umls-concept:C0205208 | lld:lifeskim |
| pubmed-article:20309652 | lifeskim:mentions | umls-concept:C0023779 | lld:lifeskim |
| pubmed-article:20309652 | lifeskim:mentions | umls-concept:C0074554 | lld:lifeskim |
| pubmed-article:20309652 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:20309652 | lifeskim:mentions | umls-concept:C1450054 | lld:lifeskim |
| pubmed-article:20309652 | lifeskim:mentions | umls-concept:C0038215 | lld:lifeskim |
| pubmed-article:20309652 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
| pubmed-article:20309652 | lifeskim:mentions | umls-concept:C2698650 | lld:lifeskim |
| pubmed-article:20309652 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:20309652 | pubmed:dateCreated | 2010-6-18 | lld:pubmed |
| pubmed-article:20309652 | pubmed:abstractText | The objective of this study was to develop solid lipid nanoparticles (SLNs) of simvastatin and to optimize it for independent variables (amount of glycerol monostearate, concentration of poloxamer, and volume of isopropyl alcohol) in order to achieve desired particle size with maximum percent entrapment efficiency (% EE) and percent cumulative drug release (% CDR). To achieve our goal, eight formulations (F(1)-F(8)) of SLNs were prepared by solvent injection technique and optimized by 2(3) full-factorial design. The design was validated by extra design checkpoint formulation (F(9)), and the possible interactions between independent variables were studied. The responses of the design were analyzed using Design Expert 7.1.6. (Stat-Ease, Inc, USA), and the analytical tools of software were used to draw Pareto charts and response surface plots. On the basis of software analysis, formulation F(10) with a desirability factor of 0.611 was selected as optimized formulation and was evaluated for the independent parameters. Optimized formulation showed particle size of 258.5 nm, % EE of 75.81%, with of 82.67% CDR after 55 h. The release kinetics of the optimized formulation best fitted the Higuchi model, and the recrystallization index of optimized formulation was found to be 65.51%. | lld:pubmed |
| pubmed-article:20309652 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20309652 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20309652 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20309652 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20309652 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20309652 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20309652 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20309652 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20309652 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20309652 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20309652 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20309652 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20309652 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20309652 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20309652 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20309652 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:20309652 | pubmed:issn | 1530-9932 | lld:pubmed |
| pubmed-article:20309652 | pubmed:author | pubmed-author:PathakKamlaK | lld:pubmed |
| pubmed-article:20309652 | pubmed:author | pubmed-author:ShahMayankM | lld:pubmed |
| pubmed-article:20309652 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20309652 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:20309652 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20309652 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20309652 | pubmed:pagination | 489-96 | lld:pubmed |
| pubmed-article:20309652 | pubmed:dateRevised | 2011-7-26 | lld:pubmed |
| pubmed-article:20309652 | pubmed:meshHeading | pubmed-meshheading:20309652... | lld:pubmed |
| pubmed-article:20309652 | pubmed:meshHeading | pubmed-meshheading:20309652... | lld:pubmed |
| pubmed-article:20309652 | pubmed:meshHeading | pubmed-meshheading:20309652... | lld:pubmed |
| pubmed-article:20309652 | pubmed:meshHeading | pubmed-meshheading:20309652... | lld:pubmed |
| pubmed-article:20309652 | pubmed:meshHeading | pubmed-meshheading:20309652... | lld:pubmed |
| pubmed-article:20309652 | pubmed:meshHeading | pubmed-meshheading:20309652... | lld:pubmed |
| pubmed-article:20309652 | pubmed:meshHeading | pubmed-meshheading:20309652... | lld:pubmed |
| pubmed-article:20309652 | pubmed:meshHeading | pubmed-meshheading:20309652... | lld:pubmed |
| pubmed-article:20309652 | pubmed:meshHeading | pubmed-meshheading:20309652... | lld:pubmed |
| pubmed-article:20309652 | pubmed:meshHeading | pubmed-meshheading:20309652... | lld:pubmed |
| pubmed-article:20309652 | pubmed:meshHeading | pubmed-meshheading:20309652... | lld:pubmed |
| pubmed-article:20309652 | pubmed:meshHeading | pubmed-meshheading:20309652... | lld:pubmed |
| pubmed-article:20309652 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20309652 | pubmed:articleTitle | Development and statistical optimization of solid lipid nanoparticles of simvastatin by using 2(3) full-factorial design. | lld:pubmed |
| pubmed-article:20309652 | pubmed:affiliation | Department of Pharmaceutics, Rajiv Academy for Pharmacy, National Highway #2, P.O. Chhattikara, Mathura, Uttar Pradesh, 281001, India. | lld:pubmed |
| pubmed-article:20309652 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20309652 | lld:pubmed |
